The Scientific Basis of Heart Failure in the Young

年轻人心力衰竭的科学依据

• 批准号: 7277969
• 负责人: Ronald Mark Payne
• 金额: $ 1万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7277969
• 关键词: Adult; Area; Attention; Basic Science; Cardiac; Cardiomyopathies; Child; Clinical; Clinical Sciences; Collaborations; Colorado; Congenital Abnormality; Congenital Heart Defects; Embryology; Etiology; Financial cost; Future; Genes; Goals; Heart; Heart Diseases; Heart failure; Incidence; Infant; Inherited; Injury; Knowledge; Life; Literature; Maps; Molecular; Morbidity - disease rate; Morphogenesis; Myocarditis; Operative Surgical Procedures; Participant; Population; Public Health; Regulation; Research; Research Personnel; Risk; Today; Translations; Underserved Population; base; concept; congenital heart disorder; day; design; falls; improved; mortality; novel; pre-clinical; programs; response; social; symposium; tool; young adult

DESCRIPTION (provided by applicant): Heart failure (HF) in the young is a common clinical entity that has significant morbidity and mortality and carries substantial long-term social and financial costs. The leading cause is congenital heart disease, which is the most common birth defect with an incidence of almost 1%. It is also the 5th ranked cause of years of potential life lost at 2 per 1000 population. Well over 450,000 children and over 1 million adults in the USA have a congenital heart defect emphasizing its impact on public health. In addition, inherited cardiomyopathies, and acquired heart disease, such as myocarditis, contribute to the overall burden of HF in the young. Despite the importance of HF in young adults, children and infants, it has been less well studied when compared with the rich literature and basic understanding of HF in adults. As a result, therapy for children with HF has advanced more slowly. Indeed, most new concepts for management of HF in children today are based on translation of adult treatment strategies with little preclinical evidence supporting their use in the young. However, recent and exciting discoveries in the molecular regulation of cardiac morphogenesis, as well as in the cellular and molecular response of the heart to injury, have provided new tools to understand HF in the young. The goal of this 3 day conference is to present current clinical and basic research on the basis of HF in children, and map out future directions in heart failure research for this underserved population. The conference will be kept relatively small (~150 participants) in order to maintain a high quality of interaction between participants, and to remain focused on the scientific basis of HF in children. The venue for this meeting, Estes Park, Colorado, is chosen to enhance these interactions in an informal setting, and is planned for the Fall of 2007. Five broad areas of research will be presented across the 2.5 days of the meeting: 1) Basic mechanisms of HF in the young. 2) Basic and novel tools for quantifying HF. 3) Novel therapies for HF. 4) Clinical science of HF in the young. 5). Adult congenital heart disease. This conference has 4 goals: 1) Increased attention to the need for clinical and basic research on HF in the young. 2) Increased collaborations between basic and clinical researchers to focus on HF in the young. 3) Improved clinical understanding of the basis for HF and its treatment in children and young adults. 4) Increased understanding of novel concepts and new ideas for understanding HF and it's treatment in the young. Given the different etiologies of HF in the young, our rapidly advancing knowledge of gene programs directing cardiac embryology and contractile function, and the rapidly growing population of children surviving surgery who now have a high risk of late onset HF, there is an urgent need to understand HF in the young in order to design new treatment strategies and rationally apply current therapies.

描述（由申请人提供）： 年轻人心力衰竭（HF）是一种常见的临床疾病，具有显着的发病率和死亡率，并带来巨大的长期社会和经济成本。主要原因是先天性心脏病，这是最常见的出生缺陷，发病率接近 1%。这也是造成潜在寿命损失的第五大原因，每 1000 人就有 2 人因该疾病而丧失潜在寿命。美国有超过 45 万名儿童和超过 100 万成年人患有先天性心脏病，这凸显了其对公共健康的影响。此外，遗传性心肌病和获得性心脏病（例如心肌炎）也会增加年轻人心力衰竭的总体负担。尽管心力衰竭对年轻人、儿童和婴儿很重要，但与丰富的文献和对成人心力衰竭的基本了解相比，它的研究还较少。因此，心力衰竭儿童的治疗进展缓慢。事实上，当今儿童心力衰竭治疗的大多数新概念都是基于成人治疗策略的转化，几乎没有临床前证据支持其在年轻人中的使用。然而，最近在心脏形态发生的分子调节以及心脏对损伤的细胞和分子反应方面的令人兴奋的发现，为了解年轻人的心力衰竭提供了新的工具。这次为期 3 天的会议的目标是介绍当前基于儿童心力衰竭的临床和基础研究，并为这一服务不足的人群制定心力衰竭研究的未来方向。会议规模将保持相对较小（约 150 名参与者），以保持参与者之间的高质量互动，并继续关注儿童心力衰竭的科学基础。此次会议的举办地点是科罗拉多州埃斯蒂斯公园，旨在加强非正式环境中的这些互动，计划于 2007 年秋季举行。在 2.5 天的会议中将介绍五个广泛的研究领域： 1) 年轻人心力衰竭的基本机制。 2) 量化 HF 的基本和新颖工具。 3）心力衰竭的新疗法。 4）青少年心力衰竭的临床科学。 5）。成人先天性心脏病。本次会议有4个目标：1）更加关注年轻人心衰临床和基础研究的需求。 2）加强基础和临床研究人员之间的合作，重点关注年轻人的心力衰竭。 3) 提高了对儿童和青少年心力衰竭基础及其治疗的临床认识。 4) 增加对年轻人心力衰竭及其治疗的新概念和新想法的理解。鉴于年轻人心力衰竭的病因不同，我们对指导心脏胚胎学和收缩功能的基因程序的了解迅速发展，以及手术后幸存儿童的数量迅速增长，他们现在具有晚发性心力衰竭的高风险，迫切需要了解年轻人心力衰竭，以便设计新的治疗策略并合理应用现有疗法。